Tumour-induced osteomalacia: a rare cause of chronic pain and weakness.

Autor: Nasr JT; Neuroscience, Valley Hospital, Ridgewood, New Jersey, USA jnasr@neurobergen.com., Tohme J; Endocrinology, Valley Hospital, Ridgewood, New Jersey, USA., Collins MT; Skeletal Diseases and Mineral Homeostasis Section of NIDCR Disorders, National Institutes of Health, Bethesda, Maryland, USA., Drake MT; Endocrinology, Mayo Clinic, Rochester, Minnesota, USA., Hartley IR; Skeletal Diseases and Mineral Homeostasis Section of NIDCR Disorders, National Institutes of Health, Bethesda, Maryland, USA., Sfeir J; Endocrinology, Mayo Clinic, Rochester, Minnesota, USA., Dockery K; Diagnostic Imaging, Valley Hospital, Ridgewood, New Jersey, USA., Taskin M; Pathology, Valley Hospital, Ridgewood, New Jersey, USA.
Jazyk: angličtina
Zdroj: Practical neurology [Pract Neurol] 2022 Dec; Vol. 22 (6), pp. 528-531. Date of Electronic Publication: 2022 Jul 27.
DOI: 10.1136/pn-2022-003394
Abstrakt: Tumor-induced osteomalacia is a rare and often misdiagnosed condition that presents with progressively worsening unexplained chronic pain and proximal muscle weakness. The osteomalacia leads to multiple stress fractures which do not heal properly, leading to progressive disability. It is caused by chronic hypophosphatemia due to inappropriate urinary phosphate wasting. This is due to a typically benign mesenchymal tumor that over-secretes a phospaturic hormone. Neurologists need to appreciate the relevance of chronic hypophosphatemia in people with chronic unexplained pain, as timely diagnosis and treatment of tumour-induced osteomalacia can be curative.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze: MEDLINE